延长随访证实达拉非尼联合曲美替尼辅助治疗BRAF V600突变III期黑色素瘤的无复发生存获益
COMBI-AD III期试验更新分析显示,中位随访44个月(达拉非尼联合曲美替尼组)和42个月(安慰剂组),3年和4年无复发生存率联合组分别为59%和54%,安慰剂组为40%和38%(HR 0.49)。无远处转移生存亦 favoring 联合组(HR 0.53),估计治愈率联合组54% vs 安慰剂组37%。
要点
- 达拉非尼联合曲美替尼辅助治疗显著改善无复发生存(HR 0.49)。
- 无远处转移生存同样获益(HR 0.53)。
- 亚组分析显示无论基线分期、淋巴结转移负荷或溃疡状态均获益。
核心结论
- 延长随访证实达拉非尼联合曲美替尼辅助治疗可改善BRAF V600突变III期黑色素瘤患者的无复发生存。
研究设计与样本
- III期随机对照试验,患者为已切除的BRAF V600突变III期黑色素瘤,随机接受12个月辅助达拉非尼联合曲美替尼或安慰剂。
主要发现
- 中位随访44个月(联合组)和42个月(安慰剂组),3年无复发生存率联合组59%(95%CI 55-64),安慰剂组40%(95%CI 35-45)。
- 4年无复发生存率联合组54%(95%CI 49-59),安慰剂组38%(95%CI 34-44)。
- 无复发生存风险比HR 0.49(95%CI 0.40-0.59)。
- 无远处转移生存风险比HR 0.53(95%CI 0.42-0.67)。
- 估计治愈率联合组54%(95%CI 49-59),安慰剂组37%(95%CI 32-42)。
关键数值与推荐
- 亚组分析显示无复发生存获益在基线疾病分期(AJCC第7和第8版)、淋巴结转移负荷和溃疡状态亚组中一致。
临床怎么用
- 对于已切除的BRAF V600突变III期黑色素瘤患者,辅助达拉非尼联合曲美替尼治疗12个月可考虑作为标准选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600-mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT01682083). We present an updated RFS analysis on the basis of extended study follow-up and a cure-rate model analysis to estimate the fraction of patients expected to remain relapse free long term. METHODS: In this phase III trial, patients with resected BRAF V600-mutant stage III melanoma were randomly assigned to 12 months of adjuvant dabrafenib plus trametinib versus placebo. We report updated RFS (primary end point) and distant metastasis-free survival. RFS was also analyzed by subgroups defined by baseline disease stage (American Joint Committee on Cancer 7th and 8th editions), nodal metastatic burden, and ulceration status. The fraction of patients who remained relapse free long term was estimated using a Weibull mixture cure-rate model. RESULTS: At median follow-up of 44 months (dabrafenib plus trametinib) and 42 months (placebo), 3- and 4-year RFS rates were 59% (95% CI, 55% to 64%) and 54% (95% CI, 49% to 59%) in the dabrafenib plus trametinib arm and 40% (95% CI, 35% to 45%) and 38% (95% CI, 34% to 44%) in the placebo arm, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). Distant metastasis-free survival also favored dabrafenib plus trametinib (HR, 0.53; 95% CI, 0.42 to 0.67). The estimated cure rate was 54% (95% CI, 49% to 59%) in the dabrafenib plus trametinib arm compared with 37% (95% CI, 32% to 42%) in the placebo arm. Subgroup analysis of RFS demonstrated similar treatment benefit regardless of baseline factors, including disease stage, nodal metastatic burden, and ulceration. CONCLUSION: Longer follow-up confirmed RFS benefit with dabrafenib plus trametinib. Subgroup analysis suggested that dabrafenib plus trametinib benefited patients regardless of baseline factors.
引用
- Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018. PMID: 30343620. doi:10.1200/JCO.18.01219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。